The company is positioned to jump out of the gate come the March launch. At September 30, the company already had a specialty sales force of 73 sales professionals in place, salivating to call on high-volume (RX) prescribers and other influential neurologists who specialize in treating patients with neuromuscular disorders.
Will deeper-pocketed pharma companies looking to broaden the breadth of their own MS drug portfolios, such as Biogen Idec or Teva Pharmaceuticals, move to make an offer for Acorda prior to the March launch of Ampyra? Continue Reading….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.